Evidence map›Paper›PMID 41445693›Full record

ReviewTherapeutic advances in psychopharmacology2025

Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review.

Serene Lee, Liyang Yin, Kayla M Teopiz, Sabrina Wong, Gia Han Le, Naomi Xiao, Stephen Stahl, Kyle Valentino, Roger Ho, Melanie C Zhang and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Serene LeeBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Liyang YinBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Kayla M TeopizBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Sabrina WongBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Gia Han LeBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Naomi XiaoDepartment of Health Sciences, Queen's University, Kingston, ON, CanadaBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Stephen StahlUniversity of California, San Diego, San Diego, CA, USA.
Kyle ValentinoBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Roger HoInstitute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore, Singapore.
Melanie C ZhangDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.
Taeho Greg RheeDepartment of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
Roger S McIntyreDepartment of Psychiatry, University of Toronto, ON, Canada Department of Pharmacology and Toxicology, University of Toronto, 77 Bloor Street West, Suite 617, Toronto, ON M5S 1M2, Canada.ORCID https://orcid.org/0000-0003-4733-2523

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extant literature pertaining to the administration of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for Alzheimer's disease, Parkinson's disease, major depressive disorder, bipolar disorder, substance-, alcohol- and nicotine-use disorders, suggests promising efficacy beyond the current FDA-approved indications (e.g., type 2 diabetes mellitus, obesity). The implicated brain regions of the aforementioned mental disorders contain glucagon-like peptide 1 (GLP-1) receptors associated with improving cognitive and behavioral functioning. Therefore, we aimed to systematically review the treatment effects of GLP-1RAs in various neurocognitive and psychiatric disorders. Online databases including PubMed, OVID, MEDLINE, Embase, PsycINFO and Google Scholar, were searched from inception until October 1, 2024. Additional studies were identified from the reference lists of the included articles. 22 studies were identified, with a total of 186,847 participants included. Results reported that GLP-1RAs meaningfully improved cognitive and affective functioning (e.g., memory), which in some cases was sustained beyond exposure to the agent. Separately, multiple epidemiological studies reported that GLP-1RAs have protective effects, with a suggestion of decrease in the incidence of mental disorders. These results provides the impetus for large, long-term, randomized controlled trials for GLP-1 RAs for the treatment of various mental disorders. This review is not registered in PROSPERO or any other registry.

Indexed as

Alzheimer’s diseaseanxietydepressionliraglutidelixisenatideParkinson’s diseasesubstance use disorder

Identifiers

PMID41445693
PMCPMC12722685

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.